Outcomes of three different new generation transcatheter aortic valve prostheses.
Giuliano CostaSergio BuccheriMarco BarbantiAndrea PicciDenise TodaroEmanuela Di SimoneKetty La SpinaPaolo D'ArrigoEnrico CriscioneMarco NastasiCarmelo SgroiCorrado TamburinoPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
TAVI using new-generation prostheses was associated with high device success (97.0% vs. 92.8% vs. 95.0% for SAPIEN 3, Evolut R and ACURATE neo, respectively) and low complications rates up to 1 year. Evolut R valve was associated with a higher rate of PPI whereas SAPIEN 3 valve was associated with a higher mean transvalvular gradient and lower rate of more-than-trace PVR. At 1-year, MACCE rates were similar among the three groups.
Keyphrases
- aortic valve
- transcatheter aortic valve implantation
- aortic stenosis
- transcatheter aortic valve replacement
- aortic valve replacement
- risk factors
- heavy metals
- protein protein
- heart failure
- type diabetes
- metabolic syndrome
- coronary artery disease
- atrial fibrillation
- ejection fraction
- skeletal muscle
- small molecule
- insulin resistance
- risk assessment
- weight loss
- glycemic control